$6.39 -$0.08 (0.0%)

04:00 PM EDT on 07/16/19

Minerva Neurosciences (NASDAQ:NERV)

CAPS Rating: 3 out of 5

Current Price $6.39 Mkt Cap $282.9M
Open $6.47 P/E Ratio 0.00
Prev. Close $6.39 Div. (Yield) $0.00 (0.0%)
Daily Range $6.38 - $6.50 Volume 86,166
52-Wk Range $4.10 - $8.68 Avg. Daily Vol.

Caps

How do you think NASDAQ:NERV will perform against the market?

Add Stock to CAPS Watchlist

All Players

12 Outperform
4 Underperform
 

All-Star Players

5 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NERV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

usubanas (99.49)
Submitted February 20, 2019

Ph3 schizo mid 2019, ph2 results were solid. At ~300M MC currently, will go up 5x with good results.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:NERV VS S&P 500 (SPY)

NASDAQ:NERV Summary

Fools bearish on NASDAQ:NERV are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NERV.

Recs

1
Member Avatar usubanas (99.49) Submitted: 2/20/2019 1:04:38 AM : Outperform Start Price: $6.49 NASDAQ:NERV Score: -15.11

Ph3 schizo mid 2019, ph2 results were solid. At ~300M MC currently, will go up 5x with good results.

Recs

0
Member Avatar Bigsef77 (68.68) Submitted: 5/17/2018 4:24:01 PM : Outperform Start Price: $6.75 NASDAQ:NERV Score: -15.55

Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug
,MarketWatch•May 17, 2018

Minerva Neurosciences Inc. shares rose 5.4% in premarket trade on Thursday after results from a phase 2b trial for a schizophrenia drug were published in the peer-reviewed The Journal of Clinical Psychiatry. Patients on the therapy, roluperidone, showed cognitive improvements; the cognitive improvements were also connected to previously-reported improvements in negative symptoms, the company said. Minerva shares have surged 19.3% over the last three months, compared with a 0.4% decline in the S&P 500 and a 1.8% drop in the Dow Jones Industrial Average .

Recs

0
Member Avatar rbitrage (94.51) Submitted: 11/4/2014 4:39:50 PM : Underperform Start Price: $4.33 NASDAQ:NERV Score: +0.52

NO earnings. Currently healthcare is overly expensive and growth cannot be sustained. This small stock likely wil go to zero.

Leaderboard

Find the members with the highest scoring picks in NERV.

Score Leader

drugtrader

drugtrader (92.72) Score: +365.20

The Score Leader is the player with the highest score across all their picks in NERV.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
RafaelStock 98.95 8/1/2016 Underperform 5Y $11.08 -42.33% +38.00% +80.33 0 Comment
GrapeFool 23.91 5/26/2016 Underperform 5Y $9.57 -33.22% +43.23% +76.44 0 Comment
WildShaman 94.49 7/9/2018 Underperform 5Y $8.65 -26.13% +8.38% +34.51 0 Comment
rbitrage 94.51 11/6/2014 Underperform 5Y $4.33 +47.58% +48.10% +0.52 1 Comment
Under5 < 20 11/7/2017 Outperform 5Y $5.80 +10.17% +15.74% -5.57 0 Comment
farhangp < 20 7/9/2019 Outperform 5Y $6.70 -4.63% +1.27% -5.90 0 Comment
portefeuille2 98.69 4/29/2019 Outperform 5Y $7.29 -12.35% +2.12% -14.46 0 Comment
usubanas 99.49 1/29/2019 Outperform 5Y $6.49 -1.54% +13.57% -15.11 1 Comment
Bigsef77 68.68 5/17/2018 6/8/2018 Outperform 3Y $6.75 -5.33% +10.22% -15.55 2 Comments
jck444 92.70 2/20/2019 Outperform 5Y $7.82 -18.29% +7.77% -26.06 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NERV.

Advertisement